Xenon to Report Q2 2024 Financial Results on August 8, 2024

Rhea-AI Summary

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the results.

Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their lead product, Azetukalner, a Kv7 channel opener, is in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator in its class.

Positive

• Xenon has a novel product pipeline addressing high unmet medical needs in epilepsy and depression
• Azetukalner, the company's lead product, is in late-stage clinical development for multiple indications

Negative

• None.

Conference Call and webcast scheduled at 4:30 pm ET

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024.

Conference Call/Webcast Information:

Date:	Thursday, August 8, 2024
Time:	4:30 pm Eastern Time (1:30 pm Pacific Time)
Webcast:	Pre-register here
Dial-In:	(800) 715-9871 toll-free, or (646) 307-1963 for international callers
Conference ID:	1631616

The live audio webcast can be accessed on the Investors section of the Xenon website. A replay of the webcast will be posted on the website approximately one hour after the conclusion of the event and will remain available for approximately one month. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

FAQ

When will Xenon Pharmaceuticals (XENE) report its Q2 2024 financial results?

Xenon Pharmaceuticals (XENE) will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024.

What time is Xenon Pharmaceuticals' (XENE) Q2 2024 earnings call scheduled for?

Xenon Pharmaceuticals' (XENE) Q2 2024 earnings conference call and webcast is scheduled for 4:30 pm Eastern Time (1:30 pm Pacific Time) on Thursday, August 8, 2024.

What is Xenon Pharmaceuticals' (XENE) lead product in development?

Xenon Pharmaceuticals' (XENE) lead product is Azetukalner, a Kv7 channel opener in late-stage clinical development for multiple indications.

What therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?

Xenon Pharmaceuticals (XENE) focuses on developing therapeutics for neurological and psychiatric disorders, with a particular emphasis on epilepsy and depression.